OncoZenge AB (FRA:8LY) Insider Ownership : 0.00 % (As of Mar. 22, 2025)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OncoZenge AB's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OncoZenge AB's Institutional Ownership is 0.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OncoZenge AB's Float Percentage Of Total Shares Outstanding is 0.00%.

OncoZenge AB Insider Ownership Historical Data

The historical data trend for OncoZenge AB's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Insider Ownership Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Insider Ownership

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Insider Ownership	Get a 7-Day Free Trial												-	-	-	-	-

OncoZenge AB Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

OncoZenge AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

ONCOZ:Sweden

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines